Hypersensitivity reactions to folinic acid: mechanisms involved based on two case reports and a literature review

• Published in: Allergy, asthma, and clinical immunology Vol. 18; no. 1; p. 107
• Main Authors: Apraxine, Matveï, Van den Eynde, Marc, De Cuyper, Astrid, Pirson, Françoise
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.12.2022; BioMed Central; BMC
• Subjects: Allergic reaction; Allergy; Anaphylaxis; Cancer; Care and treatment; Case Report; Chemotherapy; Colorectal cancer; Dexchlorpheniramine; Fluorouracil; Folinic acid; G proteins; Health aspects; Hypersensitivity reaction; Immunoglobulin E; Leucovorin; Palonosetron; Panitumumab; Case report; Folinic acid; Anaphylaxis; Hypersensitivity reaction; Colorectal cancer
• ISSN: 1710-1484; 1710-1492; 1710-1492
• DOI: 10.1186/s13223-022-00752-5

Hypersensitivity reactions (HSR) to antineoplastic agents are an increasing problem, especially when they lead to treatment discontinuation, sometimes without any equivalent therapeutic option. HSR to folinic acid (FA), used particularly for the treatment of digestive carcinoma along with oxaliplatin and 5-fluorouracil, are rare. Only seven publications report HSR to FA, mainly confirmed by the disappearance of symptoms after the withdrawal of FA from chemotherapy. Only two papers describe allergy testing. Due to the difficult diagnosis, patients usually receive several further cycles of chemotherapy with progressively more intense symptoms before the withdrawal of FA. Here we document two cases of HSR to FA, initially misattributed to oxaliplatin. The first patient described successive cycles with first back muscle pain, then chills and facial oedema and finally diffuse erythema with labial edema despite premedication. The allergy assessment highlighted high acute tryptase levels and intradermal tests positive for FA, pointing to an immunoglobulin E (IgE)-mediated mechanism. The second patient also had lower back muscle pain and chills in addition to tachycardia and desaturation during the administration of FA. Skin tests were negative and tryptase levels normal. After withdrawing FA, the symptoms did not recur, thus allowing the patient to continue chemotherapy. The mechanism of FA hypersensitivity is still unclear. The chronology of symptoms suggests an IgE-mediated mechanism that was not documented in the allergy assessment. A non-IgE-mediated mast cell/basophil activation could be involved, through complement activation or through Mas-related G protein-coupled receptors X2 (MRGPRX2) particularly. These two cases of anaphylaxis to FA document the clinical manifestations associated with two different mechanisms of HSR. This paper provided the opportunity to review the limited literature on HSR to FA. Through these cases, we hope to draw the practitioner's attention to FA as a potential agent of severe hypersensitivity, especially if symptoms remain after withdrawing the most suspected chemotherapeutic agents. We want also to stress the importance of allergy testing.